Select Language
Axl
Axl Overview
| English Name | AXL receptor tyrosine kinase | Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 | Target Synonym | EC:2.7.10.1，EC 2.7.10，UFO，AXL Transforming Sequence/Gene，AXL Oncogene，EC 2.7.10.1，JTK11，Tyro7，ARK，Tyrosine-protein kinase receptor UFO，AXL，AXL Receptor Tyrosine Kinase |
| Highest Development Stage | Approved | ||
| English Name | AXL receptor tyrosine kinase |
| Target Synonym | EC:2.7.10.1，EC 2.7.10，UFO，AXL Transforming Sequence/Gene，AXL Oncogene，EC 2.7.10.1，JTK11，Tyro7，ARK，Tyrosine-protein kinase receptor UFO，AXL，AXL Receptor Tyrosine Kinase |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 30 |
| Highest Development Stage | Approved |
Axl Product List
- Product Category
Protein (4)
- Product Status
Launched (5)
- Species
Human (3)Cynomolgus (1)
- Tag
His Tag (2)Fc Tag (1)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (3)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT AXL-H82F9 |  Human | HEK293 | Biotinylated Human AXL Protein, Fc,Avitag™ (MALS verified) |  |  |  |  Add to Cart |
AXL-H5226 | Human | HEK293 | Human Axl Protein, His Tag (SPR verified) |  | |  | Add to Cart |
AXL-H5253 | Human | HEK293 | Human Axl Protein, Fc Tag (MALS verified) |  | | | Add to Cart |
AXL-C52H3 |  Cynomolgus | HEK293 | Cynomolgus Axl Protein, His Tag |  | | Add to Cart |
Total: 4
- 1
Axl Background
AXL Receptor Tyrosine Kinase is also known as Tyrosine-protein kinase receptor UFO, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. AXL contains two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. AXL is highly expressed in metastatic colon tumors. AXL is activated by GAS6-binding and subsequent autophosphorylation. AXL is involved in signal transduction from the extracellular matrix into the cytoplasm by binding growth factors, and thus implicated in the stimulation of cell proliferation.
Axl Synonyms
AXL,UFO
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| AXL inhibitor | Small molecule | Oncology/Cancer | STK11_mut NSCLC,other cancers | Phase I | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Leiomyosarcoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Batiraxcept | S6-500c; 3D-229; 3D229; 3D-299; Ruga-S6; AB-007; AVB 500; AVB-500; Aravive S-6; AVB-S6-500 | Phase 3 Clinical | Aravive Inc | Ovarian Neoplasms; Solid tumours; Glomerulonephritis, IGA; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Neoplasms; Peritoneal Neoplasms; Uterine Neoplasms; Fallopian Tube Neoplasms | Details |
| KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
| Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Mouth Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Mecbotamab vedotin | BA-3011; BA3011; BA 3011 | Phase 2 Clinical | Bioatla | Ovarian Neoplasms; Dermatofibrosarcoma; Sarcoma; Carcinoma, Non-Small-Cell Lung | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Gallbladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| Tamnorzatinib | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Leukemia; Solid tumours; Myelodysplastic Syndromes; Pancreatic Neoplasms; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
| Bemcentinib | BGB-324; R-428; BGB-3234 | Phase 2 Clinical | Rigel Pharmaceuticals Inc | Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Adenocarcinoma of Lung; Myelodysplastic Syndromes; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Glioblastoma; Central Nervous System Neoplasms; Mesothelioma; Brain Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Enapotamab vedotin | AXL-107-MMAE | Phase 2 Clinical | Seagen Inc, Genmab A/S | Solid tumours; Ovarian Neoplasms; Sarcoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| FC-084-CSA | FC084CSA; FC-084-CSA | Phase 2 Clinical | FindCure Biosciences (ZhongShan) Co Ltd | Solid tumours | Details |
| XZB-0004 | XZB-0004; SLC-0211; SLC-391 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases | Details |
| Butylidenephthalide | NSC-325307; LF-001 (Everfront Biotech); EF-001; HK-001; BDPH | Phase 2 Clinical | Everfront Biotech Co Ltd | Glioblastoma; Glioma; Amyotrophic Lateral Sclerosis | Details |
| Adrixetinib | Q-702 | Phase 2 Clinical | Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH | Lymphoma, Follicular; Central Nervous System Lymphoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Histiocytic Sarcoma; Erdheim-Chester Disease; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Neoplasms; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Stomach Neoplasms; Esophageal Neoplasms; Leukemia, Lymphoid; Solid tumours; Lymphoma, T-Cell, Peripheral | Details |
| Dubermatinib | TP-0903 | Phase 1 Clinical | Sumitomo Dainippon | Solid tumours; Ovarian Neoplasms; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| Mipasetamab uzoptirine | ADCT-601; BGB-601; 1H12-GaINAcN3; 1H12-HAKB | Phase 1 Clinical | Adc Therapeutics Sa | Solid tumours | Details |
| NP-01 (SSY Group) | Phase 1 Clinical | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Prostatic Neoplasms; Lung Neoplasms | Details | ||
| A-416 | A416; A-416 | Phase 1 Clinical | Klus Pharma Inc | Solid tumours | Details |
| NTQ-2494 | NTQ2494; NTQ-2494 | Phase 1 Clinical | Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details | |
| CTS-2016 | CTS-2016 | Phase 1 Clinical | CytosinLab Therapeutics Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| AB-801 | AB-801 | Phase 1 Clinical | Arcus Biosciences Inc | Neoplasms | Details |
| NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
| TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
| AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
| PF-07265807 | PF-07265807 | Phase 1 Clinical | Pfizer Inc | Solid tumours; Neoplasm Metastasis | Details |
| Denfivontinib Hydrochloride | SKI-G-801; G-801; G-749 Hydrochloride | Phase 1 Clinical | Genosco | Solid tumours; Leukemia, Myeloid, Acute | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms | Details |
| NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland